

Antiviral Vaccines Catalysts Tracker

April 2024


Antiviral Vaccines Catalysts

2024-2025

Antiviral Vaccine Catalysts: 2024 & 2025

Synopsis

RSV	✓ Regulatory: - JP approval (Pfizer – Maternal) - US, EU, JP, CA Regulatory submission & decision (GSK – Older Adults, aged 50-59 yrs) - US and EU approval (Moderna – Older Adults) ✓ Launch: mRNA-1345 (Moderna) and Arexvy (GSK)
Flu	✓ Trial Updates: Topline Ph3 data (Pfizer) and Moderna ✓ Regulatory: - US BLA filing (Moderna) - US sBLA approval (AstraZeneca) - US approval (Pfizer) ✓ Launch: - JP launch (AstraZeneca) - US launch (Pfizer)
COVID-19	✓ Trial Updates: Topline Ph2/3 data (AstraZeneca) ✓ Launch: SpikeVax (Moderna) in Switzerland, Brazil
CMV	✓ Trial Updates: Topline Ph3 data (Moderna)



Antiviral Vaccine Catalysts: 2024 & 2025

Key Milestones

Trial data Read-out	AstraZeneca Sipavibart Topline Ph2/3 data 12+ yrs 1H'24	Pfizer PF-07252220 Topline Ph3 data OA, 60+ yrs 2Q'24	moderna mRNA-1647 Topline Ph3 data 4Q'24	moderna mRNA-1083 Topline Ph3 data 2024			
	Regulatory /Launch	AstraZeneca FluMist intranasal sBLA (US) approval Self-administered 2Q'24	Pfizer Abrysvo Japan approval MAT 2Q'24	GSK Arexvy FDA PDUFA OA, 50-59 yrs Jun'24	GSK Arexvy Launch in Canada OA 2Q'24	moderna SpikeVax Launch in Switzerland and Brazil 2Q'24	GSK Arexvy Approval in JP, CA and EU OA, 50-59 yrs 2H'24
		moderna mRNA-1345 FDA PDUFA OA May'24	moderna mRNA-1345 EU approval OA 2H'24	moderna mRNA-1345 Launch in US, AUS, EU (OA) 2H'24	moderna mRNA-1010 BLA (US) filing 2024	AstraZeneca FluMist intranasal JP launch Self-administered 2024	Pfizer PF-07252220 US approval and launch, OA 60+ yrs 2025

RSV

COVID-19

Flu

CMV

OA: Older Adults; MAT: Maternal

 Regulatory  Readout

 Launch

Source: Biomedtracker

Disclaimer: Data extracted as of 10th April 2024. The above list is not exhaustive & only includes Ph3 and above candidates of US-based big pharma (also includes Moderna)

If you need help developing a
winning strategy,
email us at info@atacana.com